Condition: Breast Cancer · Sponsor: Novartis Pharmaceuticals
This study is designed to evaluate the effect of using the application on the adherence of patients with luminal HER2- breast cancer (BC) stage II-III to adjuvant therapy with ribociclib in combination with an aromatase inhibitor (AI). The purpose of the app is to increase adherence to treatment by informing patients about the risks of relapse and adverse event prevention and treatment.
This description comes directly from the study's public registry record.
Novartis Pharmaceuticals · +41613241111 · novartis.email@novartis.com
Novartis Pharmaceuticals
Always discuss trial participation with your own doctor first.
| Novartis Investigative Site | Pskov, Russia, Russia | Recruiting |
| Novartis Investigative Site | Moscow, Russia | Recruiting |
| Novartis Investigative Site | Saint Petersburg, Russia | Recruiting |
| Novartis Investigative Site | Saint Petersburg, Russia | Recruiting |
| Novartis Investigative Site | Saint Petersburg, Russia | Recruiting |
| Novartis Investigative Site | Sestroretsk, Russia | Recruiting |
| Novartis Investigative Site | Ufa, Russia | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06905301